Depression Screening from Voice Samples of Patients Affected by Parkinson's Disease.

Digit Biomark

Department of Neurology, University of Washington, Seattle, WA, USA Short Title: Depression Screening using Voice in Parkinson's Disease.

Published: June 2019

Depression is a common mental health problem leading to significant disability world wide. Depression is not only common but also commonly co-occurs with other mental and neurological illnesses. Parkinson's Disease gives rise to symptoms directly impairing a person's ability to function. Early diagnosis and detection of depression can aid treatment, but diagnosis typically requires an interview with a health provider or structured diagnostic questionnaire. Thus, unobtrusive measures to monitor depression symptoms in daily life could have great utility in screening depression for clinical treatment. Vocal biomarkers of depression are a potentially effective method of assessing depression symptoms in daily life, which is the focus of the current research. We have a database of 921 unique patients with Parkinson's disease and their self assessment of whether they felt depressed or not. Voice recordings from these patients were used to extract paralinguistic features, which served as inputs to machine-learning and deep learning techniques to predict depression. The results are presented here and the limitations are discussed given the nature of the recordings which lack language content. Our models achieved accuracies as high as 0.77 in classifying depressed and non-depressed subjects accurately using their voice features and PD severity. We found depression and severity of Parkinson's Disease had a correlation coefficient of 0.3936, providing a valuable feature when predicting depression from voice. Our results indicate a clear correlation between feeling depressed and the severity of the Parkinson's disease. Voice may be an effective digital biomarker to screen for depression among patients suffering from Parkinson's Disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927667PMC
http://dx.doi.org/10.1159/000500354DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
24
depression
12
patients parkinson's
8
depression common
8
depression symptoms
8
symptoms daily
8
daily life
8
severity parkinson's
8
parkinson's
6
disease
6

Similar Publications

White Matter Fiber Bundle Alterations Correlate with Gait and Cognitive Impairments in Parkinson's Disease based on HARDI Data.

Curr Med Imaging

January 2025

Department of Radiology, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong An Road, Xicheng District, Beijing 100050, China.

Background: The neuroanatomical basis of white matter fiber tracts in gait impairments in individuals suffering from Parkinson's Disease (PD) is unclear.

Methods: Twenty-four individuals living with PD and 29 Healthy Controls (HCs) were included. For each participant, two-shell High Angular Resolution Diffusion Imaging (HARDI) and high-resolution 3D structural images were acquired using the 3T MRI.

View Article and Find Full Text PDF

Nuclear Alpha-Synuclein in Parkinson's Disease and the Malignant Transformation in Melanoma.

Neurol Res Int

January 2025

Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico.

Alpha-synuclein (ASyn), a marker of Parkinson's disease (PD) and other neurodegenerative processes, plays pivotal roles in neuronal nuclei and synapses. ASyn and its phosphorylated form at Serine 129 (p-ASyn) are involved in DNA protection and repair, processes altered in aging, neurodegeneration, and cancer. To analyze the localization of p-ASyn in skin biopsies of PD patients and melanoma.

View Article and Find Full Text PDF

Objectives: Despite being recognized for a long time as a characteristic of Parkinson's disease (PD), pseudobulbar affect (PBA) is still a symptom that is underdiagnosed and undertreated. This study aimed to assess the association between PBA and various mood disturbances, as well as the impact on quality of life in PD patients.

Methods: Sixty-eight patients with PD were enrolled in this study.

View Article and Find Full Text PDF

Parkinson's disease is primarily marked by mitochondrial dysfunction and metabolic abnormalities. We recently reported that the combined metabolic activators improved the immunohistochemical parameters and behavioural functions in Parkinson's disease and Alzheimer's disease animal models and the cognitive functions in Alzheimer's disease patients. These metabolic activators serve as the precursors of nicotinamide adenine dinucleotide and glutathione, and they can be used to activate mitochondrial metabolism and eventually treat mitochondrial dysfunction.

View Article and Find Full Text PDF

The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate 'pro-aging' or 'pro-youthful' effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!